Keywords
Metformin
Type 2 diabetes
Coronary heart disease
Pancreatic islet function
Submitted : 2023-10-23
Accepted : 2023-11-07
Published : 2023-11-22
Abstract
Objective: To investigate the impact of combining liraglutide with metformin on the enhancement of pancreatic islet function in patients with type 2 diabetes and coronary heart disease. Methods: 60 patients with type 2 diabetes and coronary heart disease admitted from February 2022 to August 2023 were selected as research subjects. They were randomly assigned to either control or treatment groups, with 30 patients in each. The control group received metformin alone, while the treatment group received liraglutide in combination with metformin. Various indicators, including blood sugar levels, pancreatic islet function, and cardiac function between the two groups were compared. Results: The results of FPG, 2hPG, HbA1c, HOMA-IR, NT-proBNP, and LVEDD in the treatment group were lower than those in the control group, whereas the values of FINS, HOMA-β, E/A, and LVEF in the treatment group were higher than those in the control group (P < 0.05). Conclusion: The use of liraglutide in combination with metformin significantly benefits patients with type 2 diabetes and coronary heart disease. It leads to improved pancreatic islet function, better blood sugar control, and enhanced cardiac function. This combination therapy is recommended for clinical adoption.
References
Guo J, Sun Y, Jia W, et al., 2018, Effects of Liraglutide on Serum Inflammatory Factors and Homocysteine in Patients with Type 2 Diabetes and Coronary Heart Disease. Journal of Xinjiang Medical University, 41(11): 1347–1350.
Dong F, Ji X, Fu W, et al., 2018, Clinical Study on Liraglutide Injection Combined with Metformin Tablets in Treating Type 2 Diabetes Associated with Coronary Heart Disease. Chinese Journal of Clinical Pharmacology, 34(17): 2077–2079.
Zhou M, Gong Y, Li W, et al., 2020, Effect of Liraglutide Combined with Metformin in Treating Type 2 Diabetes Complicated with Coronary Heart Disease and Its Impact on Pancreatic Beta Cells and Cardiac Function. Journal of Naval Medicine, 41(2): 196–198.
Guo J, Zhang Y, Sun Y, et al., 2018, Effects of Liraglutide Combined with Metformin on Blood Lipid Levels and Cardiac Function in Patients with Type 2 Diabetes and Coronary Heart Disease. Chinese Journal of Evidence-Based Cardiovascular Medicine, 10(10): 1220–1223.
Pan D, 2019, Effect of Liraglutide on Serum Immune Factor Levels in Patients with Type 2 Diabetes and Coronary Heart Disease. Journal of Cardiovascular and Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, 17(8): 1229–1232.
Liang H, Han Y, 2022, Effect of Liraglutide Combined with Metformin on Patients with Type 2 Diabetes and Coronary Heart Disease. China Medical Herald, 19(19): 98–102.
Grassroots Guidelines for Cardiac Rehabilitation of Coronary Heart Disease (2020), 2021, Chinese Medical Association, Chinese Medical Association Magazine, Chinese Medical Association General Medicine Branch, et al.
Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition) (Part 1), 2021, Chinese Journal of Practical Internal Medicine, 41(8): 668–695.
Wang X, Wu Y, Luan X, 2021, Effects of Liraglutide Combined with Metformin on Left Ventricular Diastolic Function and Inflammatory Factor Levels in Patients with Type 2 Diabetes. Chinese Modern Drug Application, 15(11): 1–6.
Zhang Y, Wang X, Wang L, 2021, Application of Liraglutide Combined with Metformin in Treating Patients with Type 2 Diabetes and Coronary Heart Disease. Diabetes New World, 24(9): 80–83.
Liu H, Chen Z, Liu Y, 2021, Clinical Effects and Adverse Reactions of Liraglutide Combined with Metformin in Treating Type 2 Diabetes Complicated with Coronary Heart Disease. Chinese Medical Sciences, 11(10): 65–67.
Lin Y, 2021, Clinical Efficacy and Safety of Liraglutide Combined with Metformin in Treating Type 2 Diabetes Complicated with Coronary Heart Disease. Journal of Clinical Rational Drug Use, 14(24): 54–56.
Yu Z, 2020, The Efficacy of Liraglutide in Treating Elderly Patients with Type 2 Diabetes Complicated with Coronary Heart Disease. Heilongjiang Medicine, 33(4): 842–844.
Lu J, 2019, Study on the Effect of Liraglutide on Serum Inflammatory Factors and Homocysteine in Patients with Type 2 Diabetes and Coronary Heart Disease. Chinese Medical Guide, 17(21): 16–17.
Zhou C, Zheng J, 2022, Effects of Liraglutide on Glucose and Lipid Metabolism, Inflammatory Factors and Cardiac Events in Elderly Patients with Type 2 Diabetes and Coronary Heart Disease. Chinese Medical Science, 12(17): 102–106.